Interferon-gamma (IFN-γ)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice

Clinical and Experimental Immunology

Volumn 116, Issue 2, 1999, Pages 238-245

  Obermeier, F ^a   Kojouharoff, G ^a   Hans, W ^a   Scholmerich J ^a   Gross, V ^a   Falk, Werner ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Dextran sulphate sodium; Experimental colitis; Interferongamma nitric oxide; Tumour necrosis factor

Indexed keywords

AMINOGUANIDINE; CYTOKINE; DEXTRAN SULFATE; GAMMA INTERFERON; NITRIC OXIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; IMMUNE RESPONSE; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032941175     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00878.x     Document Type: Article

References (80)

1. 1 Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease - enhanced production during active disease. Gut 1990; 31:686-9.
2. 2 Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989; 30:835-8.
3. 3 Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94:174-81.
4. 4 Murata Y, Ishiguro Y, Itoh J, Munakata A, Yoshida Y. The role of proinflaminaLory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J Gastroenterol 1995; 30 (Suppl. 8):56-60.
5. 5 Daig R, Andus T, Aschenbrenner E, Falk W, Schölmerich J, Gross V. Increased IL-8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996; 38:216-22.
6. 6 Mitsuyama K, Toyonaga A, Sasaki E et al. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol 1994; 96:432-6.
7. 7 Schaufelberger HD, Uhr MR, McGuckin C, Logan RP, Misiewicz JJ, Gordon Smith EC, Beglinger C. Platelets in ulcerative colitis and Crohn's disease express functional interleukin-1 and interleukin-8 receptors. Eur J Clin Invest 1994; 24:656-63.
8. 8 MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 1:301-5.
9. 9 Rückert Y, Schindler U, Heinig T, Nickolaus S, Raedler A, Schreiber S. IL-4 signaling mechanisms in inflammatory bowel disease mononuclear phagocytes. Infl Bowel Dis 1996; 2:244-52.
10. 10 West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C. Interleukin-4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology 1996; 110:1683-95.
11. 11 Andus T, Daig R, Lock G, Scholmerich J, Falk W, Gross V. Balance between pro-and antiinflammatory cytokines in the colonic mucosa in inflammatory bowel disease. Gastroenterology 1995; 108:A770.
12. 12 Casini Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154:2434-40.
13. 13 Elson CO, Sartor RB, Tennyson GS, Riddel RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344-67.
14. 14 Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-74.
15. 15 Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75:253-61.
16. 16 Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4 + T cells. Immunity 1994; 1:553-62.
17. 17 Gerosa F, Paganin C, Peritt D, Paiola F, Scupoli MT, Aste Amezaga M, Frank I, Trinchieri G. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med 1996; 183:2559-69.
18. 18 Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182:1281-90.
19. 19 Kojouharoff G, Hans W, Obermeier H, Mannel DN, Andus T, Schölmerich J, Gross V, Falk W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate-induced colitis in mice. Clin Exp Immunol 1997; 107:353-8.
20. 20 Breese E, Braegger CP, Corrigan CJ, Walker Smith JA, MacDonald TT. Interleukin-2-and interferon-gamma-secrcting T cells in normal and diseased human intestinal mucosa. Immunology 1993; 78:127-31.
21. 21 Deem RL, Shanahan F, Targan SR. Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Clin Exp Immunol 1991; 83:79-84.
22. 22 Elsasser Beile U, von Kleist S, Gerlach S, Gallati H, Monting JS. Cytokine production in whole blood cell cultures of patients with Crohn's disease and ulcerative colitis. J Clin Lab Anal 1994; 8:447-51.
23. 23 Kusugami K, Fukatsu A, Tanimoto M et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophage-and epithelial cell-dependent. Dig Dis Sci 1995; 40:949-59.
24. 24 Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995; 101:428-35.
25. 25 Noguchi M, Hiwatashi N, Liu Z., Toyota T. Enhanced interferon-gamma production and B7-2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. J Gastroenterol 1995; 30 (Suppl. 8):52-55.
26. 26 Watanabe M, Takaishi H, Hosoda Y et al. CD4+ intestinal mucosal lymphocytes in the pathogenesis of Crohn's disease. J Gastroenterol 1995; 30 (Suppl. 8):73-75.
27. 27 Chenais B, Tenu JP. Involvement of nitric oxide synthase in antiproliferative activity of macrophages: induction of the enzyme requires two different kinds of signal acting synergistically. Int J Immunopharmacol 1994; 16:401-6.
28. 28 Eizirik DL, Cagliero E, Bjorklund A, Welsh N. Interleukin-1 beta induces the expression of an isoform of nitric oxide symnase in insulin-producing cells, which is similar to that observed in activated macrophages. FEBS Letters 1992; 308:249-52.
29. 29 Saito S, Nakano M. Nitric oxide production by peritoneal macrophages of Mycobacterium bovis BCG-infected or non-infected mice: regulatory role of T lymphocytes and cytokines. J Leuk Biol 1996; 59:908-15.
30. 30 Xie QW, Cho HJ, Calaycay J et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992; 256:225-8.
31. 31 Kolios G, Brown Z, Robson RL, Robertson DA, Westwick J. Inducible nitric oxide synthase activity and expression in a human colonic epithelial cell line, HT-29. Br J Pharmacol 1995; 116:2866-72.
32. 32 Boughton Smith NK, Evans SM, Hawkey CJ, Cole AT, Balsitis M, Whittle BJ, Moncada S. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993; 342:338-40.
33. 33 Grisham MB, Yamada T. Neutrophils, nitrogen oxides, and inflammatory bowel disease. Ann NY Acad Sci 1992; 664:103-15.
34. 34 Oudkerk Pool M, Bouma G, Visser JJ, Kolkman JJ, Tran DD, Meuwissen SG, Pena AS. Serum nitrate levels in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1995; 30:784-8.
35. 35 Iwashita E, Miyahara T, Hino K, Tokunaga T, Wakisaka H, Sawazaki Y. High nitric oxide synthase activity in endothelial cells in ulcerative colitis. J Gastroenterol 1995; 30:551-4.
36. 36 Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z., Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulceralive colitis and Crohn's disease. Gut 1995; 36:718-23.
37. 37 Roediger WE, Lawson MJ, Radcliffe BC. Nitrite from inflammatory cells - a cancer risk factor in ulecrative colitis? Dis Colon Rectum 1990; 33:1034-6.
38. 38 Tran DD, Visser JJ, Pool MO, Cuesta MA, Hoekman K, Pena AS, Meuwissen SG. Enhanced systemic nitric oxide production in inflammatory bowel disease. Lancet 1993; 341:1150.
39. 39 Miller MJ, Thompson JH, Zhang XJ et al. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 1995; 109:1475-83.
40. 40 Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995; 37:247-55.
41. 41 Ribbons KA, Zhang XJ, Thompson JH et al. Potential role of nitric oxide in a model of chronic colitis in rhesus macaques. Gastroenterology 1995; 108:705-11.
42. 42 Lundberg JO, Hellstrom PM, Lundberg JM, Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet, 1994; 344:1673-4.
43. 43 Gunawardana SC, Jergens AE, Ahrens FA, Niyo Y. Colonic nitrite and immunoglobulin G concentrations in dogs with inflammatory bowel disease. J Am Vet Med Assoc 1997; 211:318-21.
44. 44 Ferretti M, Gionchetti P, Rizello F et al. Intracolonic release of nitric oxide during trinitrobenzene sulfonic acid rat colitis. Dig Dis Sci 1997; 42:2606-11.
45. 45 McKenzie SJ, Baker MS, Buffinton GD, Doe WF. Evidence of oxidam-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996; 98:136-41.
46. 46 Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol 1995; 268:G673-84.
47. 47 Miller MJ, Sadowska Krowicka H, Chotinaruemol S, Kakkis JL, Clark DA. Amelioration of chronic ileitis by nitric oxide synthase inhibition. J Pharmacol Exp Ther 1993; 264:11-16.
48. 48 Neilly PJ, Gardiner KR, Rowlands BJ. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1996; 38:475-475.
49. 49 Cross AH, Misko TP, Lin RF, Hickey WF, Troller JL, Tilton RG. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994; 93:2684-90.
50. 50 Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, Xavier RJ, Podolsky DK. Peroxynitrite-induced rat colitis - a new model of colonic inflammation. Gastroenterology 1993; 105:1681-8.
51. 51 Alican I, Kubes P. A critical role for nitric oxide in intestinal barrier function and dysfunction. Am J Physiol 1996; 270:G225-37.
52. 52 McCafferty DM, Mudgett JS, Swain MG, Kubes P. Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 1997; 112:1022-7.
53. 53 Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145:3762-6.
54. 54 Havell EA. Purification and further characterization of an anti-murine interferon-gamma monoclonal neutralizing antibody. J Interferon Res 1986; 6:489-97.
55. 55 Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98:694-702.
56. 56 Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 1993; 214:11-16.
57. 57 Axelsson LG, Landstrom E, Bylund-Fellenius AC. Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Aliment Pharmacol Ther 1998; 12:925-34.
58. 58 Misko TP, Moore WM, Kasten TP et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233:119-25.
59. 59 Leib SL, Kim YS, Black SM, Tureen JH, Tauber MG. Inducible nitric oxide synthase and the effect of aminoguanidine in experimental neonatal meningitis. J Infect Dis 1998; 177:692-700.
60. 60 Mattson DL, Maeda CY, Bachman TD, Cowley AWJ. Inducible nitric oxide synthase and blood pressure. Hypertension 1998; 31:15-20.
61. 61 Okuda Y, Sakoda S, Fujimura H, Yanagihara T. Aminoguanidine, a selective inhibitor of the inducible nitric oxide synthase, has different effects on experimental allergic encephalomyelitis in the induction and progression phase. J Neuroimmunol 1998; 81:201-10.
62. 62 Laszlo F, Evans SM, Whittle BJ. Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. Eur J Pharmacol 1995; 272:169-75.
63. 63 Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, Tjoeng FS, Currie MG. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 1995; 273:15-24.
64. 64 Corbett JA, Mikhael A, Shimizu J, Frederick K, Misko TP, McDaniel ML, Kanagawa O, Unanue ER. Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process. Proc Natl Acad Sci USA 1993; 90:8992-5.
65. 65 Seo HG, Takata I, Nakamura M, Tatsumi H, Suzuki K, Fujii J, Taniguchi N. Induction of nitric oxide synthase and concomitant suppression of superoxide dismutases in experimental colitis in rats. Arch Biochem Biophys 1995; 324:41-47.
66. 66 Grisham MB, Specian RD, Zimmerman TE. Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. J Pharmacol Exp Ther 1994; 271:1114-21.
67. 67 Yamada T, Sartor RB, Marshall S, Specian RD, Grisham MB. Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. Gastroenterology 1993; 104:759-71.
68. 68 Kubes P, Reinhardt PH, Payne D, Woodman RC. Excess nitric oxide does not cause cellular, vascular, or mucosal dysfunction in the cat small intestine. Am J Physiol 1995; 269:G34-41.
69. 69 Chesrown SE, Monnier J, Visner G, Nick HS. Regulation of inducible nitric oxide synthase mRNA levels by LPS, INF-gamma, TGF-beta, and IL-10 in murine macrophage cell lines and rat peritoneal macrophages. Biochem Biophys Res Comm 1994; 200:126-34.
70. 70 Hausmann EH, Hao SY, Pace JL, Parmely MJ. Transforming growth factor bela 1 and gamma interferon provide opposing signals to lipopolysaccharide-activated mouse macrophages. Infect Immun 1994; 62:3625-32.
71. 71 Lau KS, Nakashima O, Aalund GR, Hogarth L, Ujiie K, Yuen J, Star RA. TNF-alpha and IFN-gamma induce expression of nitric oxide synthase in cultured rat medullary interstitial cells. Am J Physiol 1995;269:F212-7.
72. 72 Liew FY. Nitric oxide in infectious and autoimmune diseases. Ciba Found Symp 1995; 195:234-9.
73. 73 Misko TP, Trotter JL, Cross AH. Mediation of inflammation by encephalitogenic cells: interferon gamma induction of nitric oxide synthase and cyclooxygenase 2. J Neuroimmunol 1995; 61:195-204.
74. 74 Roach TI, Barton CH, Chatterjee D, Liew FY, Blackwell JM. Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide-and mycobacterial lipoarabinomannan-stimulated macrophages. Immunology 1995; 85:106-13.
75. 75 Weisz A, Cicatiello L, Esumi H. Regulation of the mouse inducible-type nitric oxide synthase gene promoter by interferon-gamma, bacterial lipopolysaccharide and NG-monomethyl-L-arginine. Biochem J 1996; 316:209-15.
76. 76 Gazzinelli RT, Eltoum I, Wynn TA, Sher A. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-alpha and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J Immunol 1993; 151:3672-81.
77. 77 Waldburger KE, Hastings RC, Schaub RG, Goldman SJ, Leonard JP. Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. Am J Pathol 1996; 148:375-82.
78. 78 Cross AH, Keeling RM, Goorha S, San M, Rodi C, Wyatt PS, Manning PT, Misko TP. Inducible nitric oxide synthase gene expression and enzyme activity correlate with disease activity in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 1996; 71:145-53.
79. 79 Goddin AJ, De Belder AJ, Villa L, Wong A, Beesley JE, Kane SP, Martin JF. Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest 1996; 26:867-72.
80. 80 Singer H, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, Stenson WF. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996; 111:871-85.